BioCentury
ARTICLE | Company News

Biogen Idec Inc, Swedish Orphan Biovitrum deal

July 14, 2014 7:00 AM UTC

Swedish Orphan Biovitrum said it received a data package from Biogen Idec regarding a preclinical hemophilia A program based on recombinant XTEN technology from Amunix Operating Inc. (Mountain View, Calif.). Swedish Orphan has 120 days to review the data package for the program, which includes potential Factor VIII Fc constructs, and determine whether it will exercise an option to add the constructs to a 2006 hemophilia deal with Biogen Idec.

The original deal between Swedish Orphan and Biogen Idec was between Biovitrum AB and Syntonix Pharmaceuticals Inc. Biogen Idec acquired Syntonix in 2007, and Biovitrum acquired Swedish Orphan International AB in 2009 and changed its name (see BioCentury, Jan. 30, 2006 & Feb. 22, 2010). ...